Israeli company Teva Pharmaceutical Industries is donating 6 million hydroxychloroquine tablets through wholesalers to U.S. hospitals by March 31, and 10 million within a month. Teva is a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.
Hydroxychloroquine sulfate is approved by the US Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus, and rheumatoid arthritis.
The Teva-manufactured drug is not approved for use in treating COVID-19. However, it is under investigation for efficacy against the novel coronavirus and has been requested by US government officials to be made available for testing purposes.
The company is also reviewing the supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients […]